Key result
PCSK9 drives prostate cancer progression by boosting intratumoral cholesterol and immunosuppression.
Why the study?
Does PCSK9 inhibition reduce prostate cancer progression and alter the tumor microenvironment in preclinical models?
Does PCSK9 inhibition reduce prostate cancer progression and alter the tumor microenvironment in preclinical models?
Answers are grounded in this paper and cite their sources.
PCSK9 promotes prostate cancer progression by enhancing intratumoral cholesterol accumulation and creating an immunosuppressive microenvironment, suggesting a potential novel therapeutic role for PCSK9 inhibitors in oncology.
INTRODUCTION: Cholesterol plays critical roles in prostate cancer (PCa) proliferation, immune evasion, and androgen signaling. PCSK9 regulates cholesterol metabolism. Its role in PCa remains unclear. OBJECTIVE: To investigate PCSK9's function in promoting PCa progression and the underlying mechanisms. METHODS: mice were generated. The anti-PCSK9 antibody evolocumab was used. Androgen receptor (AR) signaling, angiogenesis, cholesterol accumulation, immune checkpoint (IC) expression, and CD8+ T cell infiltration were examined. RNA-seq was performed on xenografts. Differentially expressed genes and pathway alterations were evaluated. RESULTS: mice exhibited reduced tumor growth, metastasis, intratumoral cholesterol, CYP17A1, SRD5A1, ABI3, CORO1A, VISTA, CD53, enhanced CD8+ T cell infiltration and OS. ABI3, CORO1A, and CD53 are novel to PCa. ABI3 and CORO1A strongly correlate with CD53, VISTA, and multiple other ICs (n = 18) in 8 independent PCa populations, including metastases and CRPCs. ABI3 and CORO1A are among 15 immune-related genes (Sig15IM) upregulated by PCSK9. Sig15IM robustly stratifies PCa recurrence. In multiple single-cell RNA-seq datasets, Sig15IM, ABI3, ABI3corrgenes (ABI3 correlated genes), CORO1A, CORO1Acorrgenes, and CD53 are predominantly expressed or upregulated in exhausted CD8+ T and Treg in PCa and eight other cancer types. CONCLUSIONS: PCSK9 promotes PCa progression via enhancing intratumoral cholesterol accumulation and shaping immunosuppressive microenvironment involving novel immunosuppressive factors: Sig15IM, ABI3, CORO1A, ABI3corrgenes, CORO1Acorrgenes, and CD53. PCSK9 facilitates VISTA expression in PCa.
No takes yet. Share an insight, caveat, or question.
Gu et al. (2026) studied Prostate cancer. PCSK9 inhibition (evolocumab) or genetic modification was evaluated on Tumor growth, metastasis, intratumoral cholesterol, and immune checkpoint expression. PCSK9 promotes prostate cancer progression by enhancing intratumoral cholesterol accumulation and shaping an immunosuppressive microenvironment involving 15 upregulated immune-related genes.
Synapse has enriched 10 related papers. Consider them for comparative context: